{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:51:33Z","timestamp":1791258693465,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jchf.2026.103238","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:44:54Z","timestamp":1785271494000},"page":"103238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nonsteroidal MRAs for Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1016","volume":"14","author":[{"given":"Akshay S.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.jchf.2026.103238_bib1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"17","key":"10.1016\/j.jchf.2026.103238_bib2","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.jchf.2026.103238_bib3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jchf.2026.103238_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jchf.2026.103238_bib5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2026.103238_bib6","unstructured":"Edelmann F. SPIRonolactone In the Treatment of Heart Failure. Paper presented at: ACC 2026; March 29, 2026; New Orleans, Louisiana, USA. https:\/\/www.tctmd.com\/slide\/spironolactone-treatment-heart-failure"},{"issue":"16","key":"10.1016\/j.jchf.2026.103238_bib7","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jchf.2026.103238_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-025-04037-3","article-title":"Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction","volume":"32","author":"Vaduganathan","year":"2026","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jchf.2026.103238_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2025.06.012","article-title":"Aldosterone and aldosterone modulation in cardio-kidney diseases","volume":"86","author":"Fioretti","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jchf.2026.103238_bib11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1161\/CIRCULATIONAHA.124.071452","article-title":"Efficacy and safety of finerenone in patients with primary aldosteronism: a pilot randomized controlled trial","volume":"151","author":"Hu","year":"2025","journal-title":"Circulation"},{"issue":"31","key":"10.1016\/j.jchf.2026.103238_bib12","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"27","key":"10.1016\/j.jchf.2026.103238_bib13","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"issue":"10458","key":"10.1016\/j.jchf.2026.103238_bib14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","article-title":"Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis","volume":"404","author":"Jhund","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jchf.2026.103238_bib15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.cjco.2025.05.021","article-title":"The effect of mineralocorticoid receptor antagonists on heart failure with nonreduced ejection fraction: a systematic review and meta-analysis","volume":"7","author":"De Luca","year":"2025","journal-title":"CJC Open"},{"issue":"1","key":"10.1016\/j.jchf.2026.103238_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jchf.2018.10.017","article-title":"Efficacy and safety of spironolactone in patients with HFpEF and chronic kidney disease","volume":"7","author":"Beldhuis","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10.1016\/j.jchf.2026.103238_bib17","doi-asserted-by":"crossref","first-page":"102778","DOI":"10.1016\/j.jchf.2025.102778","article-title":"Finerenone and cardiovascular outcomes according to baseline kidney function in patients with heart failure: the FINEARTS-HF trial","volume":"14","author":"Mc Causland","year":"2026","journal-title":"JACC Heart Fail"},{"issue":"12","key":"10.1016\/j.jchf.2026.103238_bib18","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1038\/s41591-024-03264-4","article-title":"Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes","volume":"30","author":"Vaduganathan","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.jchf.2026.103238_bib19","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1038\/s41591-024-03263-5","article-title":"Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial","volume":"30","author":"Hobbs","year":"2024","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.jchf.2026.103238_bib20","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2025.03.429","article-title":"Finerenone reduces new-onset atrial fibrillation across the spectrum of cardio-kidney-metabolic syndrome: the FINE-HEART pooled analysis","volume":"85","author":"Pabon","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jchf.2026.103238_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-8587(24)00309-7","article-title":"Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial","volume":"13","author":"Butt","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.jchf.2026.103238_bib22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40256-019-00353-5","article-title":"Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial","volume":"20","author":"Neefs","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"10.1016\/j.jchf.2026.103238_bib23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jacc.2024.09.004","article-title":"Finerenone in patients with a recent worsening heart failure event: the FINEARTS-HF trial","volume":"85","author":"Desai","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jchf.2026.103238_bib24","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ahj.2024.02.021","article-title":"Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction\u2014a secondary analysis of TOPCAT","volume":"271","author":"Szabo","year":"2024","journal-title":"Am Heart J"},{"issue":"1668","key":"10.1016\/j.jchf.2026.103238_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.58347\/tml.2023.1668e","article-title":"In brief: finerenone (Kerendia) for diabetic kidney disease","volume":"65","year":"2023","journal-title":"Med Lett Drugs Ther"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926003392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926003392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:17:21Z","timestamp":1791256641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177926003392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2213177926003392"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2026.103238","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonsteroidal MRAs for Heart Failure With Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2026.103238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier on behalf of the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}],"article-number":"103238"}}